Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2), also known as COXFA4L2, is a nuclear-encoded mitochondrial protein that acts as a subunit associated with the electron transport chain, particularly modulating Complex I and IV function depending on the organismal context[1][2][7]. Although originally thought to be a part of Complex I, further research revealed tissue- and context-dependent association, notably as a hypoxia-inducible subunit in certain conditions. NDUFA4L2 attenuates mitochondrial oxygen consumption, likely as a protective adaptation to low oxygen by inhibiting electron transport and reducing reactive oxygen species production. It is overexpressed in several cancers (e.g., clear cell renal cell carcinoma) and is associated with poor outcomes, contributing to a metabolic shift favoring glycolysis over oxidative phosphorylation[11]. Pathogenic variants and dysregulation are linked to multisystem mitochondrial diseases, including Leigh disease, cardiomyopathy, and neurodevelopmental disorders[2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2).